Drugs /

luspatercept

Back to Drugs List

Overview

Generic Name(s):
luspatercept-aamt
Trade Name(s):
Reblozyl
NCI Definition [1]:
A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. ACE-536 acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.

Clinical Trials

View Clinical Trials for luspatercept

Luspatercept has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating luspatercept, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are phase 3 (2 open).

Monosomy 7, RPN1-MECOM Fusion, and Trisomy 8 are the most frequent biomarker inclusion criteria for luspatercept clinical trials.

Myelodysplastic syndromes, myelofibrosis transformation in essential thrombocythemia, and polycythemia vera, post-polycythemic myelofibrosis phase are the most common diseases being investigated in luspatercept clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Luspatercept
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating luspatercept and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
(79-l-aspartic acid(l>d))human activin receptor type-2b (actr-iib, ec=2.7.11.30) precursor-(25-131)-peptide (extracellular domain fragment) fusion protein with triglycyl-human immunoglobulin heavy constant gamma 1 fc fragment-(8-232)-peptide dimer (114-114':117-117')-bisdisulfide, luspatercept-aamt, Reblozyl, ace-536
NCIT ID [1]:
C104012

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.